Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) have earned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.

Brokers have set a 1-year consensus price target of $18.50 for the company and are forecasting that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also assigned Aeglea BioTherapeutics an industry rank of 68 out of 265 based on the ratings given to related companies.

A number of research analysts recently issued reports on AGLE shares. BMO Capital Markets restated a “buy” rating and set a $19.00 price target on shares of Aeglea BioTherapeutics in a report on Thursday, November 10th. Zacks Investment Research downgraded Aeglea BioTherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday.

Aeglea BioTherapeutics (NASDAQ:AGLE) opened at 5.19 on Monday. The stock has a 50 day moving average price of $5.28 and a 200-day moving average price of $5.64. The company’s market cap is $69.70 million. Aeglea BioTherapeutics has a 12-month low of $3.89 and a 12-month high of $12.75.

A number of hedge funds and other institutional investors have recently made changes to their positions in AGLE. Perceptive Advisors LLC purchased a new position in Aeglea BioTherapeutics during the second quarter worth $515,000. Ghost Tree Capital LLC purchased a new position in Aeglea BioTherapeutics during the second quarter worth $243,000. VHCP Management II LLC purchased a new position in Aeglea BioTherapeutics during the second quarter worth $1,527,000. Jennison Associates LLC increased its position in Aeglea BioTherapeutics by 2.7% in the third quarter. Jennison Associates LLC now owns 1,424,947 shares of the company’s stock worth $9,131,000 after buying an additional 36,868 shares during the period. Finally, University of Texas Investment Managment Co. purchased a new position in Aeglea BioTherapeutics during the third quarter worth $3,365,000. Institutional investors own 43.67% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this story on another website, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be read at http://www.dailypolitical.com/2017/01/14/analysts-set-18-50-target-price-for-aeglea-biotherapeutics-inc-agle.html.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

5 Day Chart for NASDAQ:AGLE

Get a free copy of the Zacks research report on Aeglea BioTherapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.